RecruitingPhase 1NCT06622694
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
Studying Aplastic Anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Principal Investigator
- Jun Shi, PhD
- Intervention
- RD13-02(biological)
- Enrollment
- 15 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Regenerative Medicine Clinic Center, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06622694 on ClinicalTrials.govOther trials for Aplastic Anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07461116Adverse Effects of ATG/ALG Therapy in Aplastic AnemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07400341Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AAThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07101770A Prediction Model in Pregnant Women With Aplastic AnemiaPeking University People's Hospital
- RECRUITINGNANCT07499284A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic AnemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT06752694Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic AnemiaFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT06517641Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic AnemiaMedical College of Wisconsin
- RECRUITINGNANCT06936930Reproductive and Mental Health of Patients With Aplastic AnemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07010237Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic AnemiaInstitute of Hematology & Blood Diseases Hospital, China